Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine acts as a direct alpha‑1 adrenergic agonist. By stimulating alpha‑1 receptors on the radial iris dilator muscle, it causes the muscle to contract, pulling the iris outward and widening the pupil. This effect, combined with tropicamide’s antimuscarinic action, results in effective mydriasis.

The specific dose of Mydriasert is determined by the prescribing clinician based on the patient’s age, clinical situation, and the required degree of dilation. Typically, one drop is instilled in the target eye(s) and may be repeated after a short interval if additional dilation is needed.

Safety data for Mydriasert in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers should evaluate the individual situation before prescribing to pregnant or nursing patients.

To order Mydriasert, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details, and any necessary import documentation.

Mydriasert combines a direct alpha‑1 agonist (phenylephrine) with an antimuscarinic (tropicamide), providing faster and more predictable dilation than single‑agent drops such as atropine or cyclopentolate. The combination often requires fewer applications and yields a shorter recovery time, though individual patient response may vary.

Mydriasert should be stored at room temperature, below 25 °C, in its original packaging. Protect the container from light, moisture, and extreme temperatures. Keep the product out of reach of children and discard any solution that appears discolored or contaminated.

Mydriasert is applied as an ocular drop. The patient or clinician places the prescribed number of drops into the conjunctival sac of the intended eye(s). The eye should be gently closed for a few seconds to allow absorption, and any excess liquid can be wiped away with a clean tissue.

The most serious risks include acute angle‑closure glaucoma, severe systemic hypertension, and rare allergic reactions such as anaphylaxis. Patients with a history of narrow‑angle glaucoma or uncontrolled cardiovascular disease should be monitored closely, and any signs of severe pain, vision loss, or systemic symptoms require immediate medical attention.

Mydriasert is contraindicated in individuals with known hypersensitivity to phenylephrine, tropicamide, or any excipients in the formulation. It should also be avoided in patients with narrow‑angle or acute angle‑closure glaucoma, severe uncontrolled hypertension, and certain cardiovascular conditions unless specifically directed by a qualified eye care professional.